NCT01428908View on ClinicalTrials.gov

Immunogenicity and Safety of A Group A, C Polysaccharide Meningococcal and Type b Haemophilus Influenzal Conjugate Vaccine in Infants and Children

PHASE3CompletedINTERVENTIONAL
Enrollment

2,394

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

December 31, 2011

Study Completion Date

January 31, 2012

Conditions
Group A, C Polysaccharide MeningitisType b Haemophilus Influenza
Interventions
BIOLOGICAL

A+C+hib Conjugate Vaccine

The group A, C polysaccharide meningococcal and type b haemophilus influenzal conjugate vaccine (Wuxi Royal Biological Co., LTD, 20110101) will be administered intramuscularly on one arm, per 0.5ml dose

BIOLOGICAL

Placebo

Placebo will be administered intramuscularly on the other arm, per 0.5ml dose

BIOLOGICAL

A+C Vaccine

The group A, C polysaccharide meningococcal vaccine (Wuxi Royal Biological Co., LTD, 20101202) will be administered intramuscularly on one arm, per 0.5ml dose

BIOLOGICAL

Hib vaccine

The type b haemophilus influenzal vaccine (Sanofi Pasteur Limited) will be administered intramuscularly on the other arm, per 0.5ml dose

Trial Locations (1)

224400

Funing county Center for Disease Control and Prevention, Funing County

All Listed Sponsors
collaborator

Royal (Wuxi) Biological Co., LTD

OTHER

lead

Jiangsu Province Centers for Disease Control and Prevention

NETWORK

NCT01428908 - Immunogenicity and Safety of A Group A, C Polysaccharide Meningococcal and Type b Haemophilus Influenzal Conjugate Vaccine in Infants and Children | Biotech Hunter | Biotech Hunter